Stocks Health care ABBV
NYSE · Health careAbbVie Inc. (ABBV)
AbbVie Inc. brought in $64.4B of revenue over the twelve months to June 30, 2026, up 10.4% from a year earlier. Net income was $6.3B, a net margin of 9.8%. Operating cash flow minus capital spending left $17.8B of free cash flow in fiscal 2025. At June 30, 2026 it held $6.6B in cash against $70.8B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 3, 2026.
Key facts about AbbVie Inc.
- Net worth
- AbbVie Inc. has a market value (market cap) of $496.8B at the latest share price, and shareholders' equity of -$5.9B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $61.2B (+8.6% year on year), with net income of $4.2B. Over the 12 months to June 30, 2026: revenue $64.4B, net income $6.3B.
- Cash flow
- In fiscal 2025 operations brought in $19B of cash; after $1.2B of capital spending, free cash flow was $17.8B.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 3, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- AbbVie Inc.'s next report is expected around October 30, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
- Dividend
- AbbVie Inc. declared dividends of $6.65 per share in fiscal 2025, a yield of 2.37% at the current price.
What AbbVie Inc. does
AbbVie Inc. is a biopharmaceutical company that discovers, develops, and sells prescription drugs. Its pharmaceutical portfolio includes treatments for immunology, oncology, neuroscience, eye care, and aesthetic medicine. Its well-known products include Humira, Skyrizi, Rinvoq, Imbruvica, and Botox. The company distributes its medicines through wholesalers, pharmacies, hospitals, and clinics. Its shares trade on NYSE under the ticker ABBV.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $61.2B | $4.2B | $2.36 | $17.8B |
| 2024 | $56.3B | $4.3B | $2.39 | $17.8B |
| 2023 | $54.3B | $4.9B | $2.72 | $22.1B |
| 2022 | $58.1B | $11.8B | $6.63 | $24.2B |
| 2021 | $56.2B | $11.5B | $6.45 | $22B |
| 2020 | $45.8B | $4.6B | $2.72 | $16.8B |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ABBV ranks in Health care
Dividends
AbbVie Inc. declared $6.65 per share in fiscal 2025. At the current price that is a yield of 2.37%. It paid out $11.7B in cash dividends, 276% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | $6.65 | $11.7B | 276% |
| 2024 | $6.29 | $11B | 258% |
| 2023 | $5.99 | $10.5B | 217% |
| 2022 | $5.71 | $10B | 85% |
| 2021 | $5.31 | $9.3B | 80% |
| 2020 | $4.84 | $7.7B | 167% |
Latest SEC filings
What AbbVie Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 5, 2026Quarterly results8-KAbbVie updated its 2026 earnings guidance to reflect third-quarter acquired IPR&D and milestones expense.
- September 3, 2026
- August 18, 2026Other event 8-K
- August 5, 2026Other event 8-K
- August 3, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 10% to $17B versus the same quarter last year; diluted EPS $2.03 versus $0.52.
- July 31, 2026
- July 6, 2026
- June 24, 2026
- June 22, 2026
- June 1, 2026
What is ABBV worth? A DCF from its reported cash flow
Insider trades
What the people running AbbVie Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $8.2M worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 14, 2026 | Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICER | Exercised options | 32,710 | $2.6M |
| August 14, 2026 | Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICER | Sold | 32,710 | $8.2M |
| May 8, 2026 | Austin Roxanne SDirector | Received as pay | 1,118 | - |
| May 8, 2026 | Rapp Edward JDirector | Received as pay | 1,118 | - |
| May 8, 2026 | Falk Thomas JDirector | Received as pay | 1,118 | - |
| May 8, 2026 | Waddell Frederick HDirector | Received as pay | 1,118 | - |
| May 8, 2026 | Freyman Thomas CDirector | Received as pay | 1,118 | - |
| May 8, 2026 | Roberts Rebecca BDirector | Received as pay | 1,118 | - |
Who owns ABBV
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| AbbVie Inc.13G, passive | 9% | February 18, 2025 |
| Vanguard Capital Management13G, passive | 7.51% | April 29, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 4,210 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 149,488,412 | -1,209,713 |
| Vanguard Capital Management LLC | 115,396,098 | +515,774 |
| State Street Corp | 82,596,748 | +1,379,232 |
| Vanguard Portfolio Management LLC | 48,477,996 | -1,045,082 |
| Jpmorgan Chase & Co | 47,862,796 | -8,878,895 |
| Geode Capital Management, LLC | 46,998,433 | +260,852 |
| Morgan Stanley | 38,901,001 | +884,227 |
| Capital Research Global Investors | 30,101,551 | -1,153,235 |
| Norges Bank | 25,554,538 | new |
| Bank of America Corp | 21,237,764 | -2,699,179 |
| Fmr LLC | 20,773,786 | -988,917 |
| Northern Trust Corp | 20,558,447 | -652,935 |
| Franklin Resources Inc | 19,925,232 | +5,373,163 |
| Capital World Investors | 19,178,966 | +3,337,599 |
| Goldman Sachs Group Inc | 16,291,630 | +1,146,351 |
| Capital International Investors | 15,638,631 | +1,219,638 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 14,267,697 | +106,091 |
| Charles Schwab Investment Management Inc | 12,914,230 | -53,168 |
| Bank of New York Mellon Corp | 12,853,368 | -424,793 |
| UBS Group AG | 12,845,120 | -1,206,076 |
Insiders
20 insiders reported holding 974,692 shares in total, about $274M at the last price.
| Holder | Shares |
|---|---|
| Saleki-Gerhardt AzitaEVP, CHIEF OPERATIONS OFFICER | 197,794 |
| Michael Robert A.CHAIRMAN OF THE BOARD AND CEO, Director | 178,737 |
| Freyman Thomas CDirector | 127,869 |
| Stewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICER | 83,171 |
| Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICER | 74,430 |
| Thakkar RoopalEVP, R&D and CSO | 52,376 |
| Rapp Edward JDirector | 45,964 |
| Austin Roxanne SDirector | 39,576 |
| Reents Scott TEVP, CHIEF FINANCIAL OFFICER | 38,777 |
| Waddell Frederick HDirector | 30,076 |
Questions about ABBV
What does AbbVie Inc. do?
AbbVie Inc. is a biopharmaceutical company that discovers, develops, and sells prescription drugs. Its pharmaceutical portfolio includes treatments for immunology, oncology, neuroscience, eye care, and aesthetic medicine. Its well-known products include Humira, Skyrizi, Rinvoq, Imbruvica, and Botox. The company distributes its medicines through wholesalers, pharmacies, hospitals, and clinics. Its shares trade on NYSE under the ticker ABBV.
What is AbbVie Inc.'s net worth?
AbbVie Inc. has a market value (market cap) of $496.8B at the latest share price, and shareholders' equity of -$5.9B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is AbbVie Inc. profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $6.3B on revenue of $64.4B, a net margin of 9.8%.
How much revenue does AbbVie Inc. make?
Over the twelve months to June 30, 2026 AbbVie Inc. reported revenue of $64.4B. That is 10.4% more than a year earlier.
When did AbbVie Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 3, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the quarterly results from October 5, 2026.
When is AbbVie Inc.'s next earnings report?
AbbVie Inc.'s next report is expected around October 30, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Does AbbVie Inc. pay a dividend?
Yes. AbbVie Inc. declared dividends of $6.65 per share in fiscal 2025, a yield of 2.37% at the current price.
Similar companies
Compare ABBV with
Follow ABBV
Get an email when AbbVie Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values AbbVie Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.